Wegovy vs. Ozempic vs. Compounded Semaglutide: Which Is Right for You in 2026?

Semaglutide has three faces in 2026. There's Ozempic, the injectable approved for type 2 diabetes. There's Wegovy, the higher-dose injectable approved for weight loss. And there's compounded semaglutide, the pharmacy-made version that's been the subject of FDA enforcement actions since early 2025.

Each serves a different patient. Understanding the differences — in dose, in regulation, in cost, in risk — is the first step to making a smart decision.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist. It mimics a hormone your gut releases after eating, telling your brain you're full, slowing digestion, and reducing appetite. At high enough doses, it also causes meaningful weight loss — an average of 15% of body weight in the STEP trials for Wegovy.

All three versions contain the same active molecule. The differences are in dose, delivery, and regulatory status.

Ozempic: The Diabetes Drug That Became a Weight Loss Phenomenon

Ozempic (semaglutide 0.5mg–2mg weekly injection) is FDA-approved for type 2 diabetes and cardiovascular risk reduction in adults with diabetes and established heart disease. It's not approved for weight loss — but doctors can prescribe it off-label, and many do.

Who it's for: Adults with type 2 diabetes, or adults with diabetes and high cardiovascular risk.

Cost: List price around $935–$1,000/month. With insurance for diabetes: often $25–$100/month. Without insurance: cash programs via NovoCare can bring it lower, but coverage for weight loss alone is rare.

Key fact: Ozempic doses top out at 2mg. Wegovy goes to 2.4mg, which is why Wegovy produces greater average weight loss.

Wegovy: The Approved Weight Loss Option

Wegovy (semaglutide 2.4mg weekly injection) is FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. In 2024, FDA also approved it to reduce cardiovascular risk in people with obesity and established heart disease.

Who it's for: Adults who meet BMI criteria and want a medically approved, highest-dose semaglutide option.

Cost: List price around $1,350/month. Insurance coverage for weight loss has improved but remains inconsistent — many plans still exclude obesity drugs. Through TrumpRx (launched early 2026), uninsured patients can access Wegovy for approximately $350/month at participating pharmacies.

Key fact: Wegovy produces the strongest average weight loss of any semaglutide product — 15% over 68 weeks in STEP 1. But you have to tolerate a 16–20 week dose escalation to get there.

Compounded Semaglutide: The Access Option — Now Under Pressure

During the Ozempic and Wegovy shortage (2022–2025), compounding pharmacies began producing their own semaglutide formulations. Prices ranged from $150–$400/month — a fraction of brand-name cost. Telehealth companies like Hims & Hers, LifeMD, and many others built entire GLP-1 businesses on compounded supply.

That window is closing.

The FDA officially resolved the semaglutide shortage in February 2025 and the tirzepatide shortage in late 2024. Once a shortage ends, the legal basis for compounding at scale evaporates. As of early 2026, the FDA has taken enforcement actions against non-FDA-approved compounded GLP-1s and filed actions against compounding pharmacies and telehealth companies still selling them.

Who it's for: Was the option for price-sensitive patients during the shortage. In 2026, supply is increasingly constrained and legality uncertain. Patients currently on compounded semaglutide need a transition plan.

Cost: $150–$400/month historically. Availability narrowing fast.

Key fact: Compounded drugs are not FDA-approved, which means no guarantee of quality, potency, or sterility. The FDA has flagged cold-chain violations and misrepresentation of compounded GLP-1s as “generic” equivalents — which they are not.

Side-by-Side Comparison

Factor	Ozempic	Wegovy	Compounded Semaglutide
FDA-approved for weight loss	No (diabetes only)	Yes	No
Max dose	2mg/week	2.4mg/week	Varies
Average weight loss	~6–7% (diabetes dose)	~15% (STEP trials)	Unknown (no trials)
Monthly cost (uninsured)	~$350 (TrumpRx) or $1,000 list	~$350 (TrumpRx) or $1,350 list	$150–$400 (if available)
Regulatory status (2026)	FDA-approved	FDA-approved	Under enforcement pressure
Quality guarantee	Yes (Novo Nordisk)	Yes (Novo Nordisk)	No

The 2026 Decision Framework

If you have type 2 diabetes and insurance: Ozempic is often covered for diabetes management. Start there. If your doctor agrees weight loss is a priority, Wegovy may be accessible too — coverage is improving.

If you have obesity and no diabetes, and can afford brand-name: Wegovy is the right call. It's FDA-approved for your situation, produces the best results, and TrumpRx pricing makes it more accessible than it's been in years.

If cost is the primary barrier: The calculation has shifted. Compounded semaglutide is becoming harder to access and comes with real quality and legal uncertainty. Before choosing a compounding pharmacy, verify they're a licensed 503A or 503B facility, that your provider is legitimate, and that you have a plan for what happens if supply gets cut off.

If you want a pill, not a shot: The oral semaglutide Wegovy pill (FDA-approved early 2026) changes the equation for injection-averse patients. Monthly pricing is similar to injectable Wegovy for higher doses.

The Bottom Line

All three deliver semaglutide. Wegovy delivers it at the highest, most studied dose with the clearest regulatory standing. The compounded window is closing — the FDA has made that clear. For patients currently on compounded semaglutide, now is the time to talk to a provider about a transition plan.

The good news: with TrumpRx, manufacturer programs, and new telehealth options, the cost gap between compounded and brand-name has narrowed significantly. The FDA-approved path is more accessible in 2026 than it's been in years.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting or changing any medication.

Last updated: March 2026